Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014)

Marker Therapeutics (MRKR) posted quarterly Convertible Debt of $52942.0 for Q4 2014, down 90.68% quarter-over-quarter from $568127.0 in Q3 2011.

Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014) Analysis & Trends

Marker Therapeutics (MRKR) has reported Convertible Debt for 2 consecutive years, with $52942.0 the latest figure, recorded in Q4 2014.

In Q4 2014, Convertible Debt changed N/A year-over-year to $52942.0; the TTM figure through Dec 2014 stood at $52942.0 (changed N/A YoY), while the FY2014 annual figure was $52942.0, changed N/A from the prior year.
Convertible Debt fell to $52942.0 in Q4 2014 per MRKR's latest filing, from $568127.0 in the prior quarter.
Across five years, Convertible Debt topped out at $568127.0 in Q3 2011 and bottomed at $52942.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.18 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.98 Bn	77.98 Bn	3.93 Bn
3	Argenx Se	64.37 Bn	59.19 Bn	1.37 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
7	BioNTech SE	27.75 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.24 Bn	26.08 Bn	358.27 Mn
9	Royalty Pharma	27.03 Bn	26.20 Bn	-
10	Marker Therapeutics	25.07 Mn	13.14 Mn	-

Download Data